Biocon Biologics Holds Steady with Fitch: Stable ‘BB-’ Rating Signals Confidence in Biosimilars Growth

Fitch Ratings has reaffirmed the credit rating of Biocon Biologics Limited at ‘BB-’ with a stable outlook as of September 4, 2025. This affirmation reflects Fitch’s confidence in Biocon Biologics’ financial stability and operational resilience in a competitive biosimilars market. The rating agency also upheld the ‘BB’ rating on USD 800 million secured notes issued by a subsidiary of Biocon Biologics, underscoring the company’s strong credit profile amid evolving global economic and trade conditions.

 

Key Highlights and Credit Assessment:

 

Fitch Ratings assigned the ‘BB-’ issuer default rating (IDR) to Biocon Biologics for the first time in September 2024 and has now affirmed this rating, maintaining a stable outlook.

 

The ‘BB’ rating on the secured notes issued by Biocon Biologics’ subsidiary reflects confidence in the company’s debt servicing capability and asset-backed security structure.

 

Approximately 40% of Biocon Biologics’ revenues are derived from the US market, primarily through products manufactured at its facilities in India and Malaysia.

 

Fitch’s stable outlook indicates an expectation that Biocon Biologics will maintain a stable operating and financial performance over the near to medium term.

 

Market and Industry Context:

 

The US is a critical market for Biocon Biologics, and while tariffs have recently increased between the US and India, Fitch notes that significant US tariffs on pharmaceutical products are currently not factored into its base case rating but remain a potential downside risk.

 

The competitive landscape in biosimilars limits Biocon Biologics’ ability to pass on increased tariffs or costs fully to customers despite the steady demand for its products.

 

Fitch highlights that tariff-induced cost pressures could affect operating margins if trade tensions escalate or tariffs rise further, given the product pricing dynamics in the pharmaceutical sector.

 

Broader Sector and Trade Considerations:

 

The recent imposition of reciprocal tariffs by the US on Indian goods in August 2025, including a 25% levy and additional tariffs linked to specific imports, has introduced an element of uncertainty and risk in various sectors.

 

Fitch recognizes the vulnerability of Indian pharmaceutical firms with significant US exposure, especially in biosimilars.

 

While some Indian corporates have limited direct exposure to tariffs, the second-order effects on supply chains and competitive positioning may impact earnings.

 

Outlook and Strategic Positioning:

 

Fitch’s stable outlook signifies a positive yet cautious stance, indicating that while risks exist, Biocon Biologics is expected to manage them effectively through its diversified manufacturing base and steady revenue streams.

 

The company’s continued innovation, expanding biosimilars portfolio, and presence in diverse geographic markets support this stability.

 

Fitch anticipates limited direct tariff impacts on Indian IT and domestic sectors but warns of moderate risks to India’s projected 6.5% economic growth for FY26 if tariffs remain elevated.

 

Summary:

 

Fitch Ratings’ affirmation of Biocon Biologics at the ‘BB-’ level with a stable outlook underscores the company’s resilience amid a challenging global trade environment marked by US-India tariff impositions. Though tariff risks loom as a downside factor, Fitch’s analysis reflects confidence in Biocon Biologics’ robust operational foundation, diversified revenue sources, and sound credit metrics. The outlook suggests that Biocon Biologics is poised to maintain steady credit performance while navigating the competitive pharmaceutical ecosystem and evolving international trade dynamics.

 

Source: Fitch Ratings